PRME News and Press, First Trust Heitman Global Prime Real Estate ETF From 07/30/25

2025-07-30 23:51:21 ET More on Prime Medicine Prime Medicine: Pressing Forward With Lead Liver Targeting Indications Prime Medicine soars as Jones sees it as an acquisition target RFK Jr. looks to fast track rare disease drug approvals (updated) Seeking Alpha...

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its co...

2025-07-30 16:20:23 ET More on Prime Medicine Prime Medicine: Pressing Forward With Lead Liver Targeting Indications Prime Medicine soars as Jones sees it as an acquisition target RFK Jr. looks to fast track rare disease drug approvals (updated) Seeking Alpha...

-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation -- -- Multiple hotspot Prime Editors may benefit more...

2025-07-07 16:45:07 ET Prime Medicine, Inc. ( PRME ) was able to release positive data in using its Prime Editing technology therapy PM359 to treat one patient with Chronic Granulomatous Disease [CGD]. The patient was noted to have achieved restoration of NADPH oxidase activity ...

2025-07-07 12:33:54 ET More on Prime Medicine Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 RFK Jr. looks to fast track rare disease drug approvals (updated) Prime Medicine drops after cutting CGD program amid restructuring S...

2025-06-17 10:29:37 ET More on Eli Lilly, Verve Therapeutics Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript Eli Lilly: If You Don't Buy On Weight Loss Pr...

2025-05-19 10:00:32 ET More on Prime Medicine Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA How Peter Marks' FDA departure is impacting pharma, biotech st...

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 and mid-2026, respectively;...

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- ...